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Abstract
TIG3 is a tumor suppressor protein that limits keratinocyte survival during normal differentiation. It is also important in
cancer, as TIG3 level is reduced in tumors and in skin cancer cell lines, suggesting that loss of expression may be required for
cancer cell survival. An important goal is identifying how TIG3 limits cell survival. In the present study we show that TIG3
expression in epidermal squamous cell carcinoma SCC-13 cells reduces cell proliferation and promotes morphological and
biochemical apoptosis. To identify the mechanism that drives these changes, we demonstrate that TIG3 localizes near the
centrosome and that pericentrosomal accumulation of TIG3 alters microtubule and microfilament organization and
organelle distribution. Organelle accumulation at the centrosome is a hallmark of apoptosis and we demonstrate that TIG3
promotes pericentrosomal organelle accumulation. These changes are associated with reduced cyclin D1, cyclin E and cyclin
A, and increased p21 level. In addition, Bax level is increased and Bcl-XL level is reduced, and cleavage of procaspase 3,
procaspase 9 and PARP is enhanced. We propose that pericentrosomal localization of TIG3 is a key event that results in
microtubule and microfilament redistribution and pericentrosomal organelle clustering and that leads to cancer cell
apoptosis.
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Introduction
TIG3 (Tazarotene-induced gene 3), which is also called retinoic
acid receptor responder 3 (RARRES3) and retinoid-inducible gene
1 (RIG1) [1–5], is a one hundred sixty-four amino acid protein [6].
TIG3 was originally identified as increased following treatment of
cultured epidermal keratinocytes or psoriatic epidermis with the
synthetic retinoid, Tazarotene [6]. It is expressed at low levels in
hyperproliferative epidermis (e.g., squamous cell carcinoma and
psoriasis) and expression is restored by retinoid treatment [7–9]. In
retinoid-treated psoriatic epidermis, increased TIG3 expression is
associated with restoration of normal differentiation [6,10]. The
association of increased TIG3 expression with normal epidermal
phenotype suggests that TIG3 may act as a pro-differentiation
regulator. To examine the mechanism of action, we studied TIG3
function in normal human keratinocytes [10–12]. These studies
show that TIG3 is present at vanishingly low levels in keratinocytes
in monolayer culture, but is increased in differentiated raft cultures
[12].Vector-mediated expressionofTIG3inkeratinocytesresultsin
reduced proliferation and increased cornified envelope formation,
suggesting that TIG3 regulates keratinocyte differentiation [10–12].
Ongoing studies show that TIG3 operates via several mechanisms,
but a prominent mechanism of action is regulation of transgluta-
minase activity [10,11]. Type I transglutaminase (TG1) is a key
enzyme in keratinocytes and other surface epithelia that is expressed
in suprabasal differentiated cells [13–20]. Transglutaminase
catalyzes formation of M-(c-glutamyl)lysine protein-protein cross-
links to assemble the cornified envelope, an essential component of
the epidermal barrier [21,22]. Our studies suggest that TIG3 co-
localizes with TG1 leading to increased transglutaminase activity
[10,11]. Additional studies show that TIG3 reduces keratinocyte
proliferation, but does not cause apoptosis [10,11]. TIG3 consists of
anaminoterminalhydrophilicsegment and ac-terminalmembrane
anchoringdomain[6,23].Mutagenesis studies indicatethat mutants
lacking the c-terminal membrane-anchoring domain are not active
[10,11,23]. In contrast, N-terminal truncation converts TIG3 into a
protein that causes apoptosis in keratinocytes [12].
TIG3 is expressed at reduced levels in skin tumors [7]. Thus, a
major goal of the present study is to characterize the impact of
TIG3 expression in skin cancer cells. We show that restoring TIG3
expression reduces survival of epidermal squamous cell carcino-
ma cells via a mechanism that involves pericentrosomal TIG3
localization leading to altered microtubule organization and
organelle distribution. This is associated with changes in the level
of cell cycle and apoptosis regulators.
Results
TIG3 expression decreases cell number
We began by examining the impact of TIG3 on SCC-13 cell
survival. TIG3 was delivered by adenovirus infection. Fig. 1A
shows that empty vector-infected cells increase in number over
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in TIG3-expressing cells. Fig. 1B shows that TIG3 level is
maximal in the infected cells by 24 and 48 h post-infection and is
reduced by 72 h. In addition to the TIG3 monomer, we observe
accumulation of high molecular weight forms which are thought to
be covalently-crosslinked TIG3 [10–12]. As previously reported,
TIG3 is expressed at low levels in most transformed cells [10,11]
and therefore is not detected at time zero.
TIG3 decreases cell proliferation by inhibiting cell cycle
progression
We next monitored cell cycle progression. We began by
assessing the percentage of cells in S-phase using BrdU labeling.
SCC-13 cells were infected with TIG3-expressing virus and after
24 h labeled with BrdU for 2 h before detection of BrdU and
TIG3. As shown in Fig. 2A,5 4 62.8% (mean 6 SEM) of EV-
infected cells were positive for BrdU as compared to 23%64% of
TIG3-expressing cells. As shown in Fig. 2B, the most prominent
cell cycle changes are a reduction in G1 and increase in subG1
events. To investigate the mechanism responsible for these
changes, we measured the level of key cell cycle regulatory
proteins. Fig. 2C shows that cyclin-dependent kinase (cdk1, cdk2,
cdk6, cdk4) levels are not altered by TIG3, but cyclin D1 and
cyclin E levels are decreased and p21 level is increased. These
changes are consistent with reduced progression through the G1
phase and the G1/S transition. Fig. 2D shows that p21 mRNA
level increases in parallel with the increase in p21 protein.
TIG3 induces apoptosis
The presence of subG1 DNA content can be associated with cell
apoptosis. We therefore assessed the impact of TIG3 on apoptosis.
As shown in Fig. 3A, TIG3 expression activates cleavage of
procaspase 9 and procaspase 3 and generates cleaved PARP. In
addition, the pro-apoptotic regulator, Bax, is increased and the
prosurvival regulator, Bcl-XL, is reduced. Increased apoptosis can
also be observed in situ. Fig. 3B shows that very few cleaved
PARP-positive cells are observed in control cultures (161%, mean
6 SD), but that the number is markedly increased in TIG3-
positive (2368%) cultures. These findings, together with the
increase in subG1 DNA content (Fig. 2B), suggest that TIG3
induces apoptotic cell death.
TIG3 localizes at a pericentrosomal location and causes
organelle redistribution
To gain insight into the TIG3 mechanism of action we
monitored TIG3 subcellular location in tAd5-TIG3 virus-infected
cells. As shown in Fig. 4A, TIG3 (green) accumulates along the
cell periphery near the plasma membrane (arrowheads) and in a
perinuclear location (arrows), and the nuclei in TIG3-expressing
cells are reduced in size. To further assess the TIG3 location, cells
were stained to detect pericentrin, a centrosome marker. The
images in Fig. 4B reveal TIG3 staining juxtaposed with
pericentrin staining (white arrow) adjacent to the nucleus (n).
TIG3 (green) localizes in the general vicinity of pericentrin (red)
suggesting accumulation in the vicinity of the centrosome.
The centrosome is a control point for a wide range of cell
functions. It functions as the microtubule organizing center
(MTOC) which is the site of microtubule assembly [24,25]. In
addition, it replicates during cell division and the daughter
centrosomes serve to organize the mitotic spindles that guide
chromosome separation [24,26]. Importantly, the MTOC serves
as a control point for movement of molecular motor-carried cargo,
including organelles, along the microtubules [27]. Moreover,
centrosome dysfunction is associated with cell apoptosis [28]. We
therefore examined whether pericentrosomal TIG3 accumulation
alters microtubule distribution. As shown in Fig. 5A, the
microtubules in TIG3-negative cells are spread throughout the
cell in a typical lattice-type network that radiates out from the
centrosome (white arrow). In contrast, in TIG3-expressing cells
(black arrow indicates pericentrosomal TIG3), the microtubules
localize as a band (red arrows) at the cell periphery and do not
Figure 1. TIG3 decreases cell survival. Subconfluent cultures of SCC-13 cells, growing in 3.8 cm
2 wells, were infected with 10 MOI tAd5-EV or
tAd5-TIG3. At 0, 24, 48, and 72 h post-infection, cells were counted and lysates prepared. A TIG3 expression decreases cell number. Values are mean
6 SEM, n=3. Those comparisons marked by an asterisk are significantly different as determined by Student’s t-test (p,0.001). B TIG3 is detected by
immunoblot in tAd5-TIG3 infected SCC-13 cells. The monomer is visible at 18 kDa and the bracket indicates higher molecular weight crosslinked TIG3
[10,11]. Molecular weights are indicated to the left of the blot in kDa.
doi:10.1371/journal.pone.0023230.g001
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microtubule location and anchorage. This is best observed in
Fig. 5A (lower panel) which shows only the b-tubulin staining.
Microtubules in the TIG3-positive cell (left) lack centrosome-based
clustering, while the TIG3-negative cell (right) has centrosome-
anchored microtubules (white arrow). To assess the impact of
TIG3 on the microtubule network, the number of cells displaying
microtubules radiating from the centrosome was counted. As
shown in the plot, the percentage of cells displaying centrosome-
directed networks is markedly reduced in TIG3-expressing cells.
The redistribution of tubulin to the cell membrane in TIG3-
positive cells suggests that it may be insoluble. To assess this, we
prepared total cell extract from TIG3-negative and positive cells
and prepared soluble and particular (pellet) fractions. We then
assayed for b-tubulin in each fraction by immunoblot. As shown in
Fig. 5A, the membrane-localized b-tubulin does not appear in the
pellet fraction, suggesting that although it is localized at the cell
periphery at or near the membrane, it remains soluble.
The tubulin and actin networks interact extensively and so we
monitored the impact of TIG3 on actin filament distribution
(Fig. 5B). In TIG3-negative cells (EV), b-actin (red) distributes
throughout the cytoplasm. In contrast, in TIG3-positive cells
(green stain) a distinct actin filament ring forms at the nuclear
periphery (red arrow). This is shown in both a merged image and
b-actin staining alone (Fig. 5B). The number of cells displaying a
nuclear actin ring was counted. The plot shows that the
percentage of cells displaying a nuclear actin ring is markedly
increased in TIG3-expressing cells.
Because organelle movement and anchoring depend upon the
tubulin and actin networks [29], we anticipated that TIG3 may
influence organelle distribution. To assess the impact of TIG3 on
organelle location, cells were stained to detect GM130 (cis-Golgi),
mannose-6-phosphate receptor (M6PR, trans-Golgi and late
endosome) [30], rab11 (recycling endosomes), calnexin (endoplas-
mic reticulum), and clathrin heavy chain (CHC, intracellular
transport vesicles). Fig. 6A shows that GM130 (red) localizes at a
perinuclear location in TIG3-negative and positive cells; however,
it appears more compacted in TIG3-positive (green stain) cells.
M6PR, rab11 and calnexin also appear compacted at the
pericentrosomal location in TIG3-positive cells (white arrows).
This is readily visualized for calnexin, by comparing the dis-
tribution shown in the red single-color image (insert) with that
observed in EV-infected cells (Fig. 6A), as an intense pericen-
trosomal concentration of calnexin is observed in TIG3-positive
cells. In addition, clathrin heavy chain is a particularly dramatic
example, in that staining appears distributed throughout the
cytoplasm in EV-infected cells, but essentially all of the CHC
accumulates in the vicinity of the centrosome in TIG3-positive
cells. Thus it appears that TIG3 alters intracellular organelle
distribution in a manner that concentrates and compresses many
organelles in the vicinity of the centrosome. This compaction was
quantified by measuring the two-dimensional area covered by
individual organelles in square microns using ImageJ Software
(Fig. 6B). This analysis reveals a substantial and statistically
significant reduction in area for GM130, M6PR and rab11.
Calnexin and CHC distribution was not analyzed in this manner,
since the condensation was obvious. We also examined the impact
of TIG3 on organelle protein level. Fig. 7 shows that TIG3
expression causes a modest reduction in the level of some organelle
proteins, including calnexin, rab11, GM130 and EEA1; however,
the level of other marker proteins is not altered.
Discussion
TIG3 (Tazarotene-induced gene 3) was originally identified as
increased following treatment of cultured epidermal keratinocytes
or psoriatic epidermis with the synthetic retinoid, Tazarotene [6],
and was later identified in gastric cancer cells and called RIG1 [5].
Subsequent studies reveal TIG3 mRNA in a range of tissues and
cells in culture [1,5,31–33]. TIG3 level is increased by retinoid
Figure 2. TIG3 reduces cell cycle progression. A SCC-13 cells
grown on coverslips were infected with 10 MOI of EV or TIG3-encoding
virus and after 24 h treated with 10 mM BrdU for 2 h and then fixed and
stained with anti-BrdU (red) and anti-TIG3 (green). BrdU incorporation is
a marker of the synthesis phase of the cell cycle. The number of BrdU
positive cells as a percentage of total cell number is presented beneath
each panel. The values are mean 6 SEM (n=3) and the values are
significantly different as determined by Student’s t-test (p,0.001).
Bars=10 mm. B SCC-13 cells were collected for flow cytometry at 24 h
post-infection with EV or TIG3-encoding virus. Cells were stained with
50 mg/ml propidium iodide prior to analysis. TIG3 reduces events in G1
and increases subG1 events. C At 24 h post-infection, cells were
harvested and extracts prepared for detection of cell cycle regulatory
proteins. Molecular weights are indicated to the left of the blot in kDa.
D Cells were treated as above and then harvested for detection of p21
encoding mRNA by real time-PCR. A similar result was observed in each
of three experiments.
doi:10.1371/journal.pone.0023230.g002
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suppressed by MAPK signaling [35].
TIG3 is a member of the NIpC/P60 superfamily of proteins [36].
The N-terminal domain (aa1–134) encodes regions that are
conserved among members of the lecithin:retinol acyltransferase
(LRAT) and H-rev tumor suppressor families [37–39]. Function-
al analysis of the TIG3 structure indicates that the c-terminal
hydrophobic domain (aa135–164) functions as a membrane anchor
[6,23] and that the N-terminal region encodes calcium-independent
phospholipase A1/2 activity [31,32,40]. Moreover, phospholipase
A1/2 activity does not require the c-terminal hydrophobic domain
[40]. TIG3 has been shown to reduce cell survival in a number of
cell types [6,10,11,34,41,42], but the mechanism responsible for the
suppressionisnotwellunderstood.Insomecelltypes,TIG3mayact
via regulation of MAPK and PI3K/Akt signaling [1,3,41].
TIG3 in epidermis
TIG3 is expressed in the suprabasal differentiated layers of
keratinocyte raft cultures [12] and in suprabasal epidermis [7,8],
and TIG3 expression is reduced in hyperproliferative skin disease
and in skin cancer cells [6–9]. Retinoid treatment increases TIG3
level and this is associated with reduced cell proliferation [6–9].
TIG3 is not expressed in normal keratinocytes maintained
in monolayer culture and vector-mediated TIG3 expression is
associated with reduced cell number [8,10–12]. Mechanistic studies
in keratinocytes show that the c-terminal membrane anchoring
domain is required for activity [10,11,23], and that expression of
TIG3 in normal human cultured keratinocytes activates selected
differentiation-related events [10–12]. In particular, TIG3 interacts
with type I transglutaminase (TG1) to increase TG1 catalytic
activity [10,11]. TG1 is a key enzyme in differentiating keratino-
cytes that catalyzes formation of protein-protein crosslinks leading
to assembly of the cornified envelope, an important component of
the skin permeability barrier [43]. Full-length TIG3 protein
stimulates differentiation-associated transglutaminase activity in
keratinocytes. In contrast, amino-terminal truncated forms cause
Figure 3. TIG3 induces apoptosis. A SCC-13 cells were infected with 10 MOI of EV or TIG3-encoding virus and after 24 h lysates were prepared for
detection of apoptosis markers. The bracket indicates high molecular weight crosslinked TIG3 [10,11]. Molecular weights are indicated to the left of
the blot in kDa. B At 24 h post-infection SCC-13 cells were fixed and stained with anti-cleaved PARP (red). TIG3 increases cleaved PARP staining. The
percentage of cleaved PARP positive cells is presented in each panel (mean 6 SD). The arrows indicate cleaved PARP-positive cells. Similar results
were observed in each of three experiments.
doi:10.1371/journal.pone.0023230.g003
Figure 4. TIG3 localizes in the vicinity of pericentrin. A SCC-13
cells were infected with 10 MOI tAd5-EV or tAd5-TIG3 and at 24 h post-
infection were fixed and stained with anti-TIG3 (green). Arrows indicate
pericentrosomal and arrowheads indicate membrane localization. No
TIG3 is detected in empty vector-infected cells. B Cells, infected as
above, were fixed and stained with TIG3 (green) and pericentrin (red).
The arrows indicate pericentrin staining of the centrosome and n
indicates the nuclei. Bars=10 mm.
doi:10.1371/journal.pone.0023230.g004
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terminus is shortened [12]. Other studies point to unique effects of
various TIG3 subdomains [40,42,44]. The suprabasal pattern of
TIG3 expression in epidermis is consistent with a role of TIG3 as a
controller of keratinocyte differentiation-related events.
TIG3 expression in skin cancer cells reduces proliferation
and increases apoptosis
Previous studies indicate that TIG3 mRNA is present at reduced
levels in skin cancer and in skin cancer cell lines [8]. However, little is
known regarding whether TIG3 regulates skin cancer cell survival
and tumor progression. We show that expression of TIG3 causes a
marked reduction in SCC-13 cell number that is associated with
reduced G1 and S phase events and increased sub-G1 DNA content.
These cell cycle changes are associated with TIG3-dependent
changes in cell cycle regulatory protein level. TIG3 expression
reduces cyclin D1 and cyclin E levels and increases the level of the
p21 cyclin-dependent kinase inhibitor. These findings are consistent
with a reduction in cell progression through the G1/S transition. In
addition, we demonstrate that TIG3 increases SCC-13 cell apoptosis
as evidenced by increased production of activated caspase 9 and 3
and increased cleaved PARP. Moreover, immunostaining studies
reveal cleaved PARP accumulates in TIG3-positive cells. These
resultsareparticularlyinterestingasTIG3doesnotcauseapoptosisin
normal human keratinocytes. Instead, TIG3 causes the cells to
undergo differentiation [10–12]. In contrast, mutant forms of TIG3
cause apoptosis in normal human keratinocytes [12]. The fact that
TIG3 causes apoptosis in cancer cells suggests a different mechanism
of action in normal versus transformed cells. In addition, some of
thesechangesare associated with changes in target gene mRNA level.
Figure 5. TIG3 alters microtubule distribution. A SCC-13 cells were infected with 10 MOI tAd5-EV or tAd5-TIG3 and at 24 h post-infection cells
were fixed and stained with anti-TIG3 (green stain) and anti-b-tubulin (red stain). TIG3 accumulates at the expected perinuclear location (black arrow).
b-tubulin accumulates in an atypical ring at the cell periphery (red arrows). The normal b-tubulin network in the TIG3-negative cell is indicated by a
white arrow pointing to the centrosome. Nuclei were Hoechst stained (blue). The bottom panel is identical to the top, except that only the b-tubulin
(red) signal is indicated. Bars=10 mM. The graph shows the number of tAd-EV and tAd5-TIG3 infected cells with centrosome-originated microtubule
arrays. Cells were counted in twenty independent microscope fields and a minimum of one-hundred cells were counted per treatment group. The
values are mean 6 SEM. Paired Student’s t-test analysis reveals that the means are significantly different (p,0.001). To assess the impact of TIG3 on
tubulin solubility, cells were infected with tAd5-EV or tAd5-TIG3 and after 24 h total extract, soluble and pellet fractions were prepared and
electrophoresed followed by immunostaining to detect b-tubulin and b-actin. The presence of the majority of b-actin in the soluble fraction indicates
that the fractionation was successful. B TIG3 expression causes actin filament collapse around the nucleus. SCC-13 cells were infected with adenovirus
as above and after 24 h stained with anti-b-actin (red stain) and anti-TIG3 (green stain). Nuclei were Hoechst stained (blue). For the TIG3-positive cells,
the left panel shows the TIG3 and b-actin signals (red and green), while the right panel shows only the b-actin (red) channel. The black arrow indicates
TIG3 accumulation at the centrosome and the red arrow indicates the b-actin microfilament nuclear ring. Bars=10 mm. The plot shows the number of
tAd-EV and tAd5-TIG3 infected cells displaying actin microfilament rings surrounding the nucleus. Cells were counted in eighteen independent
microscope fields and a minimum of one-hundred cells were counted per treatment group. The values are mean 6 SEM. Paired Student’s t-test
analysis reveals that the means are significantly different (p,0.001).
doi:10.1371/journal.pone.0023230.g005
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sociated with a parallel increase in p21 encoding mRNA, indicating
that TIG3 regulates p21 gene transcription or RNA stability. We do
not presently know whether this action is direct or indirect.
TIG3 expression is associated with pericentrosomal
organelle clustering
An important question is where TIG3 is localized in the cell. An
interesting previous study in HeLa cervical cancer cells suggests
that TIG3 localizes in the cis- and trans-Golgi and that this
localization is required to stimulate apoptosis [2]. As shown in
Fig. 6A, antibody co-staining of SCC-13 cells suggests that TIG3
localizes in the cis- and trans-Golgi (GM130, M6RP), the late
endosome (M6PR), the recycling endosome (rab11), the endoplas-
mic reticulum (calnexin) and the intracellular transport vesicles
(CHC). However, we believe that is it unlikely that TIG3 is
principally localized in these structures for several reasons. First,
TIG3 only appears to localize with the organelle only in the
immediate vicinity of the centrosome and not more peripherally.
Second, we show that TIG3 alters microtubule and microfilament
distribution and this is associated with pericentrosomal organelle
accumulation. Third, in another report we are studying the
Figure 6. Pericentrosomal organelle accumulation in TIG3-positive cells. A SCC-13 cells were infected by 10 MOI tAd5-EV or tAd5-TIG3 and
after 24 h fixed and stained to detect TIG3 (green) and various organelle markers (red). The markers include GM130 (cis-Golgi), M6PR (mannose-6-
phosphate receptor, trans-Golgi and late endosome), rab11 (recycling endosome), calnexin (ER), and CHC (clathrin heavy chain, intracellular transport
vesicle). White arrows indicate pericentrosomal localization of TIG3. Nuclei are stained blue. For GM130, M6PR, and rab11, all panels are red/green/
blue merged images. The EV and TIG3 pictures of calnexin staining are red/green/blue merged images. The inserts in the TIG3/calnexin picture are
single-color images. For the CHC stain, only the red (CHC) image is shown. Bars=10 mm. B TIG3 impact on subcellular organelle distribution. To
measure organelle spread, the microscope was focused on the z-plane displaying the maximal organelle spread and the area covered by the
organelle was monitored using ImageJ Software and presented as organelle area in mm
2. The values are mean 6 SEM (n=30 fields) including
measurement of a minimum of thirty cells per treatment group. Paired Student’s t-test analysis identifies the means as significantly different
(p,0.001).
doi:10.1371/journal.pone.0023230.g006
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studies strongly suggest a pericentrosomal TIG3 location (not
shown). Based on these findings, we argue that the major effect
of TIG3 is at the centrosome and that the appearance of
colocalization of TIG3 with organelle markers is an artifact due to
pericentrosomal organelle clustering.
Organelle relocation is a well-known phenomenon that occurs
during apoptosis [45]. It is thought to enhance organelle
membrane mixing to facilitate spread of pro-apoptotic effectors
[45–50]. However, how these organelles and organelle fragments
come together during apoptosis it is not well understood, but
is thought to involve the centrosome and microtubules. The
centrosome serves as a microtubule organizing center (MTOC) in
interphase cells and as an organizer of the mitotic apparatus in
mitotic cells. As a microtubule nucleation center, centrosome
function is required for intracellular organelle trafficking [24,51].
Organelles move along microtubules associated with specific
motor proteins [27,51]. Previous reports implicate microtubule
motors in bringing organelle and organelle fragments to the
microtubule organizing center (centrosome) during apoptosis
[45,52]. These include the Golgi apparatus, endosomes, endo-
plasmic reticulum, mitochondria and other organelles [45,
47,53,54]. The best characterized example is redistribution of
mitochondria to the Golgi-proximal microtubule organizing
center in cells exposed to TNFa, oxidative stress or viral infection
[45]. Several reports suggest that this process activates MAPK
signaling to phosphorylate kinesin light chain to halt mitochondria
anterograde dispersal leading to accumulation of these organelles
near the centrosome [45].
These previous reports describe pericentrosomal organelle
clustering in response to treatment with growth factors, oxidative
stress or other stimuli [45]. Our present studies are unique in
that the organelle clustering is triggered by expression of a tumor
suppressor protein. Moreover, the fact that TIG3 accumulates
near the centrosome suggests that it may have a direct role in
regulation of organelle movement during apoptosis. Our studies
reveal that TIG3 presence alters the normal subcellular location of
microtubules and microfilaments, which may be one mechanism
whereby it alters organelle location. Future studies will need to
address whether TIG3 also alters microtubule motor-dependent
transport of organelles. Our working hypothesis is that TIG3 may
alter both microtubule distribution and microtubule-based motor
function to cause pericentrosomal organelle clustering. Based on
our analysis, TIG3 promotes accumulation of organelles at the
centrosome including endoplasmic reticulum, Golgi apparatus,
recycling endosomes, late endosome, and transport vesicles.
However, not all organelles are transported to the centrosome.
For example, lysosomes, as measured by detection of LAMP1,
distribute in arrays along microtubules and, in TIG3-positive cells,
this pattern is intensified (not shown). Thus, additional studies will
be necessary to understand the role of TIG3 in regulating
microtubule function and organelle transport.
Materials and Methods
Cell Culture and adenovirus infection
SCC-13 cells were obtained from American Type Culture
Collection (Rockville, MD) and were maintained in high glucose
DMEM (Gibco, 11960-044) supplemented with 2 mM L-gluta-
mine, 1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml
streptomycin and 5% fetal bovine serum (Sigma, St. Louis, MO).
Adenoviruses were produced as previously described [10]. tAd5-
TIG31–164, is a tetracycline-inducible virus that encodes the full-
length TIG3 protein and a tetracycline-responsive enhancer
element [10,11]. The Ad5-TA virus encodes the tetracycline
transactivator (TA). tAd5-EV is an empty virus used as a control.
For infection, cells were washed with PBS, incubated with 10 MOI
of TIG3-encoding or empty virus in the presence of 5 MOI of
Ad5-TA in DMEM containing 6 mg polybrene/ml (Sigma,
H9268). After 5 h, the medium was replaced with virus-free
medium and incubation was continued for an additional 24–72 h
prior to preparation of cells and extracts for immunohistology and
immunoblot.
Immunological methods
For immunoblot, extracts were prepared in cell lysis buffer
(20 mM Tris-HCl, pH 7.5, containing 150 mM NaCl, 1 mM
ethyleneglycol-bis(aminoethylether)-tetraacetic acid, 1 mM EDTA,
1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM
glycerophosphate, 1 mM sodium vanadate, 1 mg/ml leupeptin
(Cell Signaling, 9803, Danvers, MA) and 1 mM phenylmethylsul-
fonyl fluoride. Protein concentration was determined using the
Bradford Bio-Rad protein assay (Bio-Rad, 500-0006). Equal
amounts of protein were electrophoresed on Ready Gels (Bio-
Rad,Hercules,CA)and transferred to nitrocellulosemembranes for
detection of proteins using the appropriate antibodies. For
immunofluorescence, cells maintained on coverslips, were infected
with adenoviruses and after 24–72 h fixed in 4% paraformalde-
hyde, permeabilized with methanol, and incubated with rabbit anti-
TIG3 (1:100) and selected organelle marker antibodies followed by
AlexaFluor488-conjugatedgoatanti-rabbitIgG(1:1000)andAlexa
Fluor 555-conjugated goat anti-mouse IgG (1:1000) secondary
antibodies. Cells were then incubated with Hoechst 33258 (1:2000),
washed thoroughly and mounted on slides using Fluoromount
(Sigma, F4680). Confocal cell images were taken using an Olympus
IX81 spinning disk confocal microscope.
Cell fractionation
SCC-13 cells were infected with 10 MOI of tAd5-EV or tAd5-
TIG3 and after 24 h the cells were collected and total extract was
prepared in cell lysis buffer. A portion of the total extract was set
aside for electrophoresis. The remaining extract was centrifuged at
14,0006g and the supernatant and pellet fraction were collected.
The pellet fraction was washed once with phosphate-buffered
saline and resuspended in gel loading buffer. Total, soluble and
pellet fractions were characterized by electrophoresis.
Figure 7. TIG3 impact on organelle marker protein level. SCC-13
cells were infected by 10 MOI tAd5-EV or tAd5-TIG3 and after 24 h cell
lysates were prepared for immunoblot detection of the indicated
proteins. TIG3 expression reduces the level of rab11, GM130 and EEA1,
but does not alter LAMP1 level. Molecular weights are indicated to the
left of the blot in kDa.
doi:10.1371/journal.pone.0023230.g007
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Polyclonal rabbit anti-TIG3 was previously described [23,55].
BrdU (B2531) and b-actin (A1978) antibodies were purchased
from Sigma. Caspase 3 (9665), Caspase 9 (9502), and cleaved
PARP (9541) antibodies were from Cell Signaling. Bcl-XL
(610211), EEA1 (610456), rab11 (610656), LAMP1 (611042),
GM130 (610822), calnexin (610524), and cyclin D1 (554180)
antibodies were purchased from BD Transduction Laboratories
(San Jose, CA). Bax (sc-493), p21 (sc-6246), cdk4 (sc-601), cdk6 (sc-
7181), cyclin E (sc-481), cdk2 (sc-163), cyclin A (sc-239), cyclin B1
(sc-245), and cdk1 (sc-54) antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). b-tubulin (ab11311), clathrin
heavy chain (ab21679), pericentrin (ab28144) and mannose-6-
phosphate receptor (ab2733) antibodies were from Abcam (Cam-
bridge, MA). Alexa Fluor 488-conjugated goat anti-rabbit (A-
11034), Alexa Fluor 555-conjugated goat anti-mouse (A-21424),
and Hoechst 33258 (H3569) were from Invitrogen (Carlsbad, CA).
Rabbit HRP-conjugated IgG (NA934) and mouse HRP-conjugat-
ed IgG (NXA931) were from GE Healthcare (Piscataway, NJ).
BrdU Incorporation and flow cytometry
To monitor BrdU incorporation, SCC-13 cells on coverslips
were infected with appropriate adenovirus and after 24 h
incubated with 10 mM BrdU (BD Pharmingen, 550891) for 2 h
at 37 C. Cells were then fixed in 4% paraformaldehyde for 30 min
at room temperature and washed with PBS containing 1% Triton
X-100. The slides were then incubated in 1 N HCl on ice for
10 min, in 2 N HCl at 25 C for 10 min and 37 C for 20 min. Cells
were then incubated with 0.1 M borate buffer for 12 min at 25 C
and washed with PBS containing 1% Triton X-100. The cells were
blocked in PBS containing 1% Triton X-100, 1 M glycine, and
5% goat serum for 1 h. Sections were incubated with anti-BrdU
antibody for 16 h at 4 C. For flow cytometry, SCC-13 cells were
infected with tAd5-EV or tAd5-TIG3 and after 24 h floating and
attached cells were fixed in methanol, incubated with 20 mg/ml
RNase for 30 min at 37 C followed by 50 mg/ml propidium iodide
for 1 h prior, and the cells were collected for flow cytometric
analysis.
Real Time-PCR
SCC-13 cells were infected with tAd5-EV or tAd5-TIG3 and at
24–48 h harvested for isolation of mRNA using the illustra
RNAspin Mini Isolation Kit (GE Healthcare, 25-0500-71). cDNA
was synthesized from isolated RNA using SuperScript III Reverse
Transcriptase (Invitrogen, 18080-044) following the manufactur-
er’s protocol. RT-PCR was performed using LightCycler 480
SYBR Green I Master (Roche, 04707516001). RT–PCR primer
sequences include: TIG3 (59-CAGTATTGTGAGCAGGAACT-
GTGA, 59-TTGGCCTTTTCCACCTGTTTAC), human cyclo-
philin (59-CATCTGCACTGCCAAGACTGA, 59-TTCATGCC-
TTCTTTCACTTTGC), and human p21 (59-AAGACCATGT-
GGACCTGTCACTGT, 59-AGGGCTTCCTCTTGGAGAAG-
ATCA).
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